PMV Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at December 31, 2023 | 51,445,862 | $— | $535,468 | $224 | $(310,003) | $225,689 |
| Stock-based compensation expense | — | — | 2,610 | — | — | 2,610 |
| Net loss | — | — | — | — | (15,270) | (15,270) |
| Unrealized loss on investments | — | — | — | (319) | — | (319) |
| Foreign currency translation loss | — | — | — | (34) | — | (34) |
| Balance at March 31, 2024 | 51,445,862 | $— | $538,078 | $(129) | $(325,273) | $212,676 |
| Exercise of stock options and common stock issued under the 2020 ESPP | 76,263 | — | 141 | — | — | 141 |
| Stock-based compensation expense | — | — | 2,767 | — | — | 2,767 |
| Net loss | — | — | — | — | (1,213) | (1,213) |
| Unrealized loss on available for sale investments | — | — | — | (61) | — | (61) |
| Foreign currency translation gain | — | — | — | 5 | — | 5 |
| Balance at June 30, 2024 | 51,522,125 | $— | $540,987 | $(185) | $(326,486) | $214,316 |
| Release of vested restricted stock units issued under the 2020 EIP | 227,379 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,224 | — | — | 2,224 |
| Net loss | — | — | — | — | (19,226) | (19,226) |
| Unrealized gain on available for sale investments | — | — | — | 591 | — | 591 |
| Foreign currency translation gain | — | — | — | 4 | — | 4 |
| Balance at September 30, 2024 | 51,749,504 | $— | $543,210 | $410 | $(345,712) | $197,908 |
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2024 | 51,935,134 | $— | $544,653 | $139 | $(368,712) | $176,080 |
| Exercise of stock options | 19,001 | — | 10 | — | — | 10 |
| Stock-based compensation expense | — | — | 1,508 | — | — | 1,508 |
| Net loss | — | — | — | — | (17,436) | (17,436) |
| Unrealized loss on investments | — | — | — | (62) | — | (62) |
| Foreign currency translation gain | — | — | — | 7 | — | 7 |
| Balance at March 31, 2025 | 51,954,135 | $— | $546,171 | $84 | $(386,148) | $160,107 |
| Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units | 1,039,103 | — | 103 | — | — | 103 |
| Stock-based compensation expense | — | — | 1,668 | — | — | 1,668 |
| Net loss | — | — | — | — | (21,210) | (21,210) |
| Unrealized loss on investments | — | — | — | (61) | — | (61) |
| Foreign currency translation loss | — | — | — | (2) | — | (2) |
| Balance at June 30, 2025 | 52,993,238 | $— | $547,942 | $21 | $(407,358) | $140,605 |
| Stock-based compensation expense | — | — | 1,383 | — | — | 1,383 |
| Net loss | — | — | — | — | (21,059) | (21,059) |
| Unrealized gain on available for sale investments | — | — | — | 69 | — | 69 |
| Foreign currency translation gain | — | — | — | 1 | — | 1 |
| Balance at September 30, 2025 | 52,993,238 | $— | $549,325 | $91 | $(428,417) | $120,999 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.